{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:16:38Z","timestamp":1768216598575,"version":"3.49.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      To investigate the therapeutic and preventive effects of the probiotic\n                      <jats:italic>Pediococcus acidilactici<\/jats:italic>\n                      PA53 on high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) in mice, and to evaluate its efficacy compared to curcumin (a well-recognized anti-NAFLD agent), thereby advancing the mechanistic and practical understanding of probiotic-based interventions for metabolic liver diseases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The experiment comprised five groups: Control group, Model group, PA53 prevention group, PA53 treatment group, and curcumin group. NAFLD was induced by feeding mice a high-fat diet (HFD), with body weight recorded weekly. At the end of the experiment, serum, liver, and ileum samples were collected from the mice. The levels of serum inflammatory factors, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and interferon-inducible protein-10 (IP-10), as well as related blood biochemical markers such as alanine aminotransferase (ALT), glucose (GLU), triglyceride (TG), cholesterol (CHO), and low-density lipoprotein cholesterol (LDL-C), were measured. Hepatic lipid deposition was evaluated using hematoxylin and eosin (H&amp;amp;E) staining and oil red O staining. Additionally, fecal samples were collected at multiple time points and subjected to 16sRNA sequencing to assess changes in the gut microbiota.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PA53 significantly attenuated body weight gain, liver lipid accumulation, serum inflammatory cytokine levels while normalizing gut microbiota composition in mice, bringing these parameters closer to those of the control group. Compared to curcumin, PA53 proved more effective in controlling body weight gain and reducing liver fat accumulation. Furthermore, the preventive regimen yielded better outcomes than the therapeutic effect. While PA53 was less effective than curcumin in modulating certain immune responses and reducing specific cytokines (such as IL-6, IL-1\u03b2, TNF-\u03b1 and IP-10), it still exerted significant anti-inflammation effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, PA53 demonstrates potential efficacy in mitigating HFD-induced NAFLD in mice, with its preventive effect appearing comparatively more prominent. Notably, PA53 exhibited superior performance over curcumin in key metabolic endpoints, which furnishes novel empirical evidence for its putative role in NAFLD management and augments the current body of knowledge regarding probiotic-based therapeutic strategies for metabolic liver diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1743709","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:14:32Z","timestamp":1768205672000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Pediococcus acidilactici PA53 in preventing high-fat diet-induced non-alcoholic fatty liver disease in mice"],"prefix":"10.3389","volume":"16","author":[{"given":"Yue","family":"Niu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shurui","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1172\/jci186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1141\u201354","DOI":"10.1002\/ueg2.70072","article-title":"The rising global burden of MASLD and other metabolic diseases (2000-2021)","volume":"13","author":"Danpanichkul","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2024.00311","article-title":"Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024)","volume":"12","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156028","article-title":"The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus","volume":"161","author":"Zeng","year":"2024","journal-title":"Metabolism"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309990","article-title":"The gut microbiota and host health: a new clinical frontier","volume":"65","author":"Marchesi","year":"2016","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-025-01318-6","article-title":"Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Kim","year":"2025","journal-title":"Nat Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-025-01300-2","article-title":"Viewing MASLD through an integrative gut microbiome lens","volume":"7","author":"Wen","year":"2025","journal-title":"Nat Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1038\/s41467-022-34671-1","article-title":"Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism","volume":"13","author":"Lei","year":"2022","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.07.007","article-title":"Microbiota and fatty liver disease-the known, the unknown, and the future","volume":"28","author":"Lang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/ijms23052689","article-title":"Pediococcus acidilactici CECT9879 (pA1c) Counteracts the Effect of a High-Glucose Exposure in C. elegans by Affecting the Insulin Signaling Pathway (IIS)","volume":"23","author":"Yavorov-Dayliev","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.821685","article-title":"Pediococcus acidilactici Promotes the Longevity of C. elegans by Regulating the Insulin\/IGF-1 and JNK\/MAPK Signaling, Fat Accumulation and Chloride Ion","volume":"9","author":"Hu","year":"2022","journal-title":"Front Nutr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5455\/javar.2023.j653","article-title":"Effect of fermented milk Pediococcus acidilactici BK01 on cholesterol and microbiota in Wistar mice intestine","volume":"10","author":"Melia","year":"2023","journal-title":"J Adv Vet Anim Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1039\/d3fo01651j","article-title":"Pediococcus acidilactici (pA1c\u00ae) alleviates obesity-related dyslipidemia and inflammation in Wistar rats by activating beta-oxidation and modulating the gut microbiota","volume":"14","author":"Yavorov-Dayliev","year":"2023","journal-title":"Food Funct"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.crfs.2022.04.009","article-title":"Pediococcus acidilactici FZU106 alleviates high-fat diet-induced lipid metabolism disorder in association with the modulation of intestinal microbiota in hyperlipidemic rats","volume":"5","author":"Zhang","year":"2022","journal-title":"Curr Res Food Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1712984","article-title":"Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome","volume":"11","author":"Lee","year":"2020","journal-title":"Gut Microbes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1002\/ctm2.634","article-title":"Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease","volume":"11","author":"Yu","year":"2021","journal-title":"Clin Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1039\/d1fo01608c","article-title":"Pediococcus acidilactici CCFM6432 mitigates chronic stress-induced anxiety and gut microbial abnormalities","volume":"12","author":"Tian","year":"2021","journal-title":"Food Funct"},{"key":"B26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12964-023-01419-3","article-title":"Pediococcus acidilactici reduces tau pathology and ameliorates behavioral deficits in models of neurodegenerative disorders","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.655258","article-title":"Pediococcus acidilactici strains improve constipation symptoms and regulate intestinal flora in mice","volume":"11","author":"Qiao","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13621","article-title":"Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases","volume":"174","author":"Kunnumakkara","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1039\/d1fo02696h","article-title":"Curcumin supplementation improves biomarkers of oxidative stress and inflammation in conditions of obesity, type 2 diabetes and NAFLD: updating the status of clinical evidence","volume":"12","author":"Mokgalaboni","year":"2021","journal-title":"Food Funct"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.1c03105","article-title":"Regulation on citrate influx and metabolism through inhibiting SLC13A5 and ACLY: A novel mechanism mediating the therapeutic effects of curcumin on NAFLD","volume":"69","author":"Sun","year":"2021","journal-title":"J Agric Food Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.555293","article-title":"The therapeutic efficacy of curcumin vs. Metformin in modulating the gut microbiota in NAFLD rats: A comparative study","volume":"11","author":"Li","year":"2020","journal-title":"Front Microbiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156998","article-title":"Trichosanthis Pericarpium injection ameliorates non-alcoholic fatty liver disease via inhibiting the KLF6\/ABCC5 pathway in mice","volume":"145","author":"Yu","year":"2025","journal-title":"Phytomedicine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156458","article-title":"Polysaccharides from hawthorn fruit alleviate high-fat diet-induced NAFLD in mice by improving gut microbiota dysbiosis and hepatic metabolic disorder","volume":"139","author":"Zhou","year":"2025","journal-title":"Phytomedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101900","article-title":"Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma","volume":"6","author":"Wu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1038\/s41467-025-58500-3","article-title":"The carotenoid torularhodin alleviates NAFLD by promoting Akkermanisa muniniphila-mediated adenosylcobalamin metabolism","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0204921","DOI":"10.1371\/journal.pone.0204921","article-title":"Comparison of the gastrointestinal tract of a dual-purpose to a broiler chicken line: A qualitative and quantitative macroscopic and microscopic study","volume":"13","author":"Alshamy","year":"2018","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e70125","DOI":"10.1002\/jev2.70125","article-title":"Umbilical cord-mesenchymal stromal cell-derived extracellular vesicles target the liver to improve neurovascular health in type 2 diabetes with non-alcoholic fatty liver disease","volume":"14","author":"Du","year":"2025","journal-title":"J Extracell Vesicles"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/nu14020386","article-title":"Switching to regular diet partially resolves liver fibrosis induced by high-fat, high-cholesterol diet in mice","volume":"14","author":"Farooq","year":"2022","journal-title":"Nutrients"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12602-025-10771-4","article-title":"Pediococcus acidilactici PA-1 alleviates diet-induced obesity by modulating hepatic amino acid metabolism and gut microbiota in mice","author":"Huang","year":"2025","journal-title":"Probiotics Antimicrob Proteins"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/pharmaceutics15041203","article-title":"Pediococcus acidilactici pA1c(\u00ae) Improves the Beneficial Effects of Metformin Treatment in Type 2 Diabetes by Controlling Glycaemia and Modulating Intestinal Microbiota","volume":"15","author":"Cabello-Olmo","year":"2023","journal-title":"Pharmaceutics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123359","article-title":"Pediococcus acidilactici CECT 9879 (pA1c\u00ae) and heat inactivated pA1c\u00ae (pA1c\u00ae HI) ameliorate gestational diabetes mellitus in mice","volume":"362","author":"Yavorov-Dayliev","year":"2025","journal-title":"Life Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1039\/d5fo01921d","article-title":"Pediococcus acidilactici KCTC 15831BP-fermented industrial hempseed (Cannabis sativa L.) supplementation corrects metabolite and gut microbiota dysbiosis, potentially mitigating Alzheimer\u2019s disease-like symptoms induced by obesity in high-fat diet-fed mice","volume":"16","author":"Aloo","year":"2025","journal-title":"Food Funct"},{"key":"B46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12906-016-1540-z","article-title":"Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers","volume":"17","author":"Al-Muzafar","year":"2017","journal-title":"BMC Complement Altern Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111781","article-title":"Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs\/miR-1205\/lncRNA SRD5A3-AS1) panel in NASH animal model","volume":"140","author":"Gadallah","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3390\/nu15082005","article-title":"Limosilactobacillus fermentum MG4294 and Lactiplantibacillus plantarum MG5289 Ameliorates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Mice","volume":"15","author":"Lee","year":"2023","journal-title":"Nutrients"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2123162","article-title":"Health effects of probiotics on nonalcoholic fatty liver in the life cycle based on data analysis","volume":"2022","author":"Wang","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-3418.2017.12.008","article-title":"Effects of Lactobacillus paracasei N1115 combined with fructooligosaccharides on non-alcoholic fatty liver disease induced by high-fat diet in mice","volume":"25","author":"Yao","year":"2017","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1039\/c8fo01227j","article-title":"Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver disease via IL-22-mediated JAK1\/STAT3\/BAX signaling","volume":"9","author":"Zhu","year":"2018","journal-title":"Food Funct"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.6133\/apjcn.042018.05","article-title":"Pro- and prebiotic effects on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease","volume":"27","author":"Javadi","year":"2018","journal-title":"Asia Pac J Clin Nutr"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjnut.2023.05.019","article-title":"Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: A randomized controlled trial","volume":"153","author":"Escouto","year":"2023","journal-title":"J Nutr"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14122","article-title":"Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature","volume":"33","author":"Haczeyni","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1002\/imt2.270","article-title":"Gut-X axis","volume":"4","author":"Lin","year":"2025","journal-title":"Imeta"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12590","article-title":"Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase \u2264 40 IU\/L and significant hepatic fibrosis","volume":"39","author":"Chao","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e001895","DOI":"10.1136\/bmjgast-2025-001895","article-title":"Liver fibrosis with persistently normal alanine transaminase levels exhibits a distinct treatment response in MASLD","volume":"12","author":"Luo","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1515\/almed-2021-0009","article-title":"Biochemical assessment of metabolic associated fatty liver disease","volume":"2","author":"Guerra-Ruiz","year":"2021","journal-title":"Adv Lab Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1039\/d2fo01343f","article-title":"\u03b1-Lactalbumin peptide Asp-Gln-Trp alleviates hepatic insulin resistance and modulates gut microbiota dysbiosis in high-fat diet-induced NAFLD mice","volume":"13","author":"Chen","year":"2022","journal-title":"Food Funct"},{"key":"B63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/mol.0000000000000154","article-title":"The immunity-diet-microbiota axis in the development of metabolic syndrome","volume":"26","author":"Brandsma","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101269","article-title":"Anthocyanins protect the gastrointestinal tract from high fat diet-induced alterations in redox signaling, barrier integrity and dysbiosis","volume":"26","author":"Cremonini","year":"2019","journal-title":"Redox Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i16.4079","article-title":"Nonalcoholic fatty liver disease as a multi-systemic disease","volume":"22","author":"Fotbolcu","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45110570","article-title":"The interconnection between hepatic insulin resistance and metabolic dysfunction-associated steatotic liver disease-the transition from an adipocentric to liver-centric approach","volume":"45","author":"Veskovi\u0107","year":"2023","journal-title":"Curr Issues Mol Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1743709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:14:34Z","timestamp":1768205674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1743709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2025.1743709"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1743709","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1743709"}}